Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Baqsimi is a prescription glucagon nasal powder used for severe hypoglycemia in adults and children age 1 and older with diabetes. Each single-use intranasal device contains one 3 mg dose of glucagon. The medicine is given into one nostril during a severe low blood sugar episode and does not need to be inhaled.
read more about baqsimi ...Glucagon activates receptors in the liver and stimulates breakdown of stored glycogen. This releases glucose from the liver into the bloodstream and raises blood glucose concentration. Adequate liver glycogen stores are needed for this action, so glucagon has reduced usefulness during starvation, adrenal insufficiency, or chronic hypoglycemia with depleted glycogen stores.
Baqsimi is approved for treatment of severe hypoglycemia in adults and pediatric patients age 1 and older with diabetes. A caregiver or other person can administer the dose when the patient cannot safely treat the low blood sugar alone. Emergency medical assistance is contacted immediately after administration.
One 3 mg dose is sprayed into one nostril using the single-use device. The patient does not need to inhale the powder. If there is no response after 15 minutes, another 3 mg dose from a new device can be given while emergency help is on the way. Oral carbohydrates are given after the patient responds and can swallow safely.
Baqsimi is contraindicated in people with pheochromocytoma, insulinoma, or prior serious hypersensitivity to glucagon or its ingredients. Serious allergic reactions have been reported. Common reactions include nausea, vomiting, headache, nasal discomfort, nasal congestion, cough, nosebleed, watery eyes, and eye redness. Glucagon can raise blood pressure sharply in people with pheochromocytoma.
Baqsimi treats severe hypoglycemia in adults and children age 1 and older with diabetes.
No. The powder is released into one nostril and does not need to be inhaled.
Yes. Another 3 mg dose from a new device can be given after 15 minutes when there is no response.
No. Each device contains one dose and is discarded after use.
BAQSIMI Important Safety Information. https://www.baqsimi.com/safety-information/. Date Accessed September 15, 2026.
DailyMed - BAQSIMI (glucagon) nasal powder. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1f5df9b-872f-44e5-a18f-f0b68e7e9254. Date Accessed September 15, 2026.
FDA Label - BAQSIMI (glucagon) Nasal Powder. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210134s004lbl.pdf. Date Accessed September 15, 2026.
Glucagon Nasal Powder. MedlinePlus. https://medlineplus.gov/druginfo/meds/a619052.html. Date Accessed September 15, 2026.
Supplement Approval Letter - BAQSIMI (glucagon) Nasal Powder. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/210134Orig1s004ltr.pdf. Date Accessed September 15, 2026.